30 March - 5 April 2019
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Mavenclad (cladribine) approved in USA
Mavenclad (cladribine) has been approved by the FDA, the US drug regulator, for relapsing forms of MS, including relapsing remitting MS and “active” secondary progressive MS. In the UK, Mavenclad has been approved as an NHS treatment since 2017.
MS Trust link: Mavenclad
Gabapentin and pregabalin reclassified
From April 1, gabapentin and pregabalin have been reclassified as controlled drugs. This has resulted in changes to how they are prescribed, particularly for repeat prescriptions.
MS Trust link: Gabapentin and pregabalin - new rules for prescriptions
Creating my MS support group helped bring over 600 people together
30 Jul 2021 - 00:00
Amy Thompson, Founder of MS Together, talks about what led her to set up the group and how it has led to new friendships this World Friendship Day.
With a little help from my furry friend
21 Jul 2021 - 00:00
Lisa, who was diagnosed with MS in 2008 tells us about how creativity and a little help from Spud the hamster helped her get through tougher times.
People with MS thoughts on freedom day
19 Jul 2021 - 00:00
From Monday the 19th of July, most covid restrictions have been lifted in England but what are people with MS really feeling about the so called "Freedom day"?
In this article we talk to some people with MS about their feelings, plus we cover what you can do if you are worried about the lifting of restrictions.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.